First author [Ref.] | Treatment success microbiological evaluation | Pathogen eradication, n/N (%) | ||
Haemophilus influenzae | Moraxella catarrhalis | Streptococcus pneumoniae | ||
Macrolides versus quinolones | ||||
Martinez 24 | 72/87 (83) versus 75/80 (94) | 21/24 (88) versus 26/27 (96) | 18/20 (90) versus 14/14 (100) | 10/11 (91) versus 11/12 (92) |
Lode 25 | 55/66 (83) versus 62/64 (97) | NA | NA | NA |
Amsden 26 | 22/23 (96) versus 17/20 (85) | 14/15 (93) versus 5/6 (83) | 7/7 (100) versus 9/10 (90) | 1/1 (100) versus 2/2 (100) |
Weiss 27 | NA | NA | NA | NA |
Wilson 28 | 44/54 (81) versus 44/47 (94) | NA | NA | NA |
Chodosh 29 | 115/127 (91) versus 265/280 (95) | 33/40 (83) versus 69/69 (100) | 24/24 (100) versus 57/58 (98) | 21/23 (91) versus 36/36 (100) |
DeAbate 30 | 108/115 (94) versus 111/116 (96) | 33/36 (92) versus 34/34 (100) | 20/20 (100) versus 29/29 (100) | 19/19 (100) versus 17/17 (100) |
Wilson 31 | 71/114 (62) versus 89/115 (77) | 23/43 (53) versus 40/44 (91) | 23/24 (96) versus 14/16 (88) | 35/36 (97) versus 32/38 (84) |
Pooled OR (95% CI) | 0.47 (0.31–0.69) | 0.18 (0.06–0.55) | 1.28 (0.32–5.19) | 1.19 (0.27–5.24) |
A/C versus quinolones | ||||
Martinez 24 | 71/89 (80) versus 70/86 (81) | 20/20 (100) versus 25/30 (83) | 16/19 (84) versus 10/12 (83) | 10/13 (77) versus 16/18 (88) |
Starakis 32 | 18/20 (89) versus 20/22 (91) | NA | NA | NA |
Schaberg 33 | 60/67 (90) versus 64/73 (88) | NA | NA | NA |
File 34 | 35/44 (80) versus 40/44 (91) | NA | NA | NA |
Pooled OR (95% CI) | 0.84 (0.49–1.42) | NA | NA | NA |
A/C versus macrolides | ||||
Anzueto 35 | 55/62 (89) versus 54/59 (92) | 18/19 (95) versus 17/20 (85) | 12/14 (86) versus 18/20 (90) | 11/14 (79) versus 11/15 (73) |
Martinot 36 | 41/55 (74) versus 55/69 (80) | 8/15 (53) versus 15/29 (52) | 3/4 (75) versus 5/6 (83) | 9/12 (75) versus 12/16 (75) |
Hoepelman 37 | 26/59 (44) versus 26/60 (43) | 16/20 (80) versus 15/21 (71) | 11/11 (100) versus 11/11 (100) | 6/6 (100) versus 9/9 (100) |
Van Royen 38 | NA | NA | NA | NA |
Biebuyck 39 | NA | NA | NA | NA |
Gris 40 | NA | NA | NA | NA |
Beghi 41 | 70/71 (99) versus 45/67 (67) | 15/15 (100) versus 13/26 (50) | 9/9 (100) versus 5/5 (100) | 34/34 (100) versus 19/27 (70) |
Dautzenberg 42 | NA | NA | NA | NA |
Pooled OR (95% CI) | 1.49 (0.51–4.39) | 2.21 (0.72–6.72) | 0.78 (0.18–3.45) | 1.96 (0.49–7.89) |
n: Number of patients affected; N: total number of patients in the study; OR: odds ratio; CI: confidence interval; NA: not available/applicable.